To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02353715
Title Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge), Abiraterone Acetate (Zytiga) or Enzalutamide (Xtandi) Undergoing Cardiopulmonary EXercise Testing
Acronym PEAX
Recruitment Completed
Gender male
Phase Phase I
Variant Requirements No
Sponsors Duke University
Indications
Therapies
Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
Duke University Medical Center Durham North Carolina 27710 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field